Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200
Debt
Debt-to-Equity RatioN/A
Current Ratio12.62
Quick Ratio12.62
Price-To-Earnings
Trailing P/E Ratio-12.36
Forward P/E Ratio-11.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.12 million
Price / Sales38.44
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.79
Profitability
EPS (Most Recent Fiscal Year)($1.88)
Net Income$-67,540,000.00
Net Margins-284.56%
Return on Equity-31.54%
Return on Assets-25.03%
Miscellaneous
Employees195
Outstanding Shares43,200,000
Market Cap$1.24 billion
Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics Inc (NASDAQ:NTLA) issued its earnings results on Wednesday, August, 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.03. The business earned $7.68 million during the quarter, compared to analysts' expectations of $6.39 million. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. Intellia Therapeutics's quarterly revenue was up 30.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.45) EPS. View Intellia Therapeutics' Earnings History.
When is Intellia Therapeutics' next earnings date?
What price target have analysts set for NTLA?
10 brokerages have issued 12-month price targets for Intellia Therapeutics' shares. Their predictions range from $28.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $41.0833 in the next year. This suggests a possible upside of 76.8% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.
What is the consensus analysts' recommendation for Intellia Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics.
What are Wall Street analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. Chardan Capital analysts commented, "We note Intellia is collaborating with the same research group at the Saraiva, who worked with Alnylam during the preclinical development of its RNAi-based therapeutics to treat ATTR. In 2010, Alnylam presented preclinical data (1, 2), also using the Porto group’s transgenic V30M mouse model, showing reductions of TTR deposition of >95% after siRNA administration every 2 weeks. Importantly, with 1 siRNA dose, TTR protein levels began to rebound within 8 days after treatment. In contrast, 1 dose of Intellia’s LNP-delivered CRISPR/Cas agent resulted in stable knockdown over 12 months, underscoring the potential advantage of the permanent nature of gene editing, though more durable RNAi formulations are now in development." (8/24/2018)
- 2. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (8/7/2018)
- 3. Cann analysts commented, "Update highlights include advancement in ex vivo development and expectations for timing of first IND. Loss per share was $0.51 compared to our estimated loss of $0.44 This primarily was the result of higher R&D of $22.5 million compared to our estimate of $19.0 million; and was partially offset by higher than expected interest income. Our revenue outlook for 2018-22 remains unchanged. We are modestly decreasing our estimated shares outstanding in 2018-22; as a result, we are making very slight adjustments to our estimated loss per share in 2019-22." (5/1/2018)
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC) and Akers Biosciences (AKER).
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Dr. John M. Leonard, Pres, CEO & Director (Age 61)
- Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 45)
- Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 52)
- Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 32)
- Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Intellia Therapeutics' major shareholders?
Intellia Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Elmwood Wealth Management Inc. (0.15%). Company insiders that own Intellia Therapeutics stock include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.
Which major investors are buying Intellia Therapeutics stock?
How do I buy shares of Intellia Therapeutics?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
One share of NTLA stock can currently be purchased for approximately $23.24.
How big of a company is Intellia Therapeutics?
Intellia Therapeutics has a market capitalization of $1.24 billion and generates $26.12 million in revenue each year. The company earns $-67,540,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Intellia Therapeutics employs 195 workers across the globe.
What is Intellia Therapeutics' official website?
How can I contact Intellia Therapeutics?
Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
